Richard S.E. Keefe

Sensory acuity and reasoning in delusional disorder.

Source-monitoring deficits for self-generated stimuli in schizophrenia: multinomial modeling of data from three sources.

Source monitoring improvement in patients with schizophrenia receiving antipsychotic medications.

Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale.

Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness.

The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery.

Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.

Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria.

Defining a cognitive function decrement in schizophrenia.

Antipsychotic drug effects on brain morphology in first-episode psychosis.

A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia.

The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome.

Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis.

Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial.

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia.

Measuring outcome priorities and preferences in people with schizophrenia.

The relationship of the Brief Assessment of Cognition in Schizophrenia (BACS) to functional capacity and real-world functional outcome.

The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity.

Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.

Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.

Optimization of a multinomial model for investigating hallucinations and delusions with source monitoring.

Baseline neurocognitive deficits in the CATIE schizophrenia trial.

Insight in first-episode psychosis.

Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial.

A longitudinal study of neurocognitive function in individuals at-risk for psychosis.

Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.

NCAM1 and neurocognition in schizophrenia.

Risperidone and cognitive function in children with disruptive behavior disorders.

Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.

Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.

Validation of the French version of the BACS (the brief assessment of cognition in schizophrenia) among 50 French schizophrenic patients.

AKT1 and neurocognition in schizophrenia.

Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.

How should DSM-V criteria for schizophrenia include cognitive impairment?

Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.

Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial.

Cognition as an outcome measure in schizophrenia.

Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study.

The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization.

The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.

Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia.

Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia.

Cognitive deficits in patients with schizophrenia: effects and treatment.

The neuregulin 1 promoter polymorphism rs6994992 is not associated with chronic schizophrenia or neurocognition.

Relationship of cognition and psychopathology to functional impairment in schizophrenia.

What CATIE found: results from the schizophrenia trial.

Should cognitive impairment be included in the diagnostic criteria for schizophrenia?

Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS).

Implementation considerations for multisite clinical trials with cognitive neuroscience tasks.

Abbreviated neuropsychological assessment in schizophrenia: prediction of different aspects of outcome.

Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America Double Blind Treatment Study.

Extrapyramidal side-effects of antipsychotics in a randomised trial.

Development and psychometric performance of the schizophrenia objective functioning instrument: an interviewer administered measure of function.

CMINDS does not have identical tests to the CATIE and MATRICS batteries. Commentary on O'Halloran et al.

Results of phase 3 of the CATIE schizophrenia trial.

Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis.

A genome-wide investigation of SNPs and CNVs in schizophrenia.

Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia.

Psychosocial factors in the neurobiology of schizophrenia: a selective review.

Measuring memory-prediction errors and their consequences in youth at risk for schizophrenia.

Memory-prediction errors and their consequences in schizophrenia.

Cognition and schizophrenia: is there a role for cognitive assessments in diagnosis and treatment?

The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial.

A brief cognitive assessment tool for schizophrenia: construction of a tool for clinicians.

Anticipating DSM-V: opportunities and challenges for cognition and psychosis.

Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study.

Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies.

Report from the working group conference on multisite trial design for cognitive remediation in schizophrenia.

Etiological and clinical features of childhood psychotic symptoms: results from a birth cohort.

The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?

The Schizophrenia Cognition Rating Scale: validation of an interview-based assessment of cognitive functioning in Asian patients with schizophrenia.

No association of the serotonin transporter polymorphisms 5-HTTLPR and RS25531 with schizophrenia or neurocognition.

Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis.

The Cognitive Assessment Interview (CAI): development and validation of an empirically derived, brief interview-based measure of cognition.

Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.

Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study.

Differential effects of emotional information on interference task performance across the life span.

Missing the sweet spot disengagement in schizophrenia.

Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial.

Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia.

Criminal justice system involvement among people with schizophrenia.

Failures in learning-dependent predictive perception as the key cognitive vulnerability to psychosis in schizophrenia.

A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia.

The MCCB impairment profile for schizophrenia outpatients: results from the MATRICS psychometric and standardization study.

Methodological issues in negative symptom trials.

Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone.

Bifactor and item response theory analyses of interviewer report scales of cognitive impairment in schizophrenia.

Comprehensive model of how reality distortion and symptoms occur in schizophrenia: could impairment in learning-dependent predictive perception account for the manifestations of schizophrenia?

Longitudinal consent-related abilities among research participants with schizophrenia: results from the CATIE study.

Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD.

Substance use and schizophrenia: adverse correlates in the CATIE study sample.

The Singapore flagship programme in translational and clinical research in psychosis.

Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far?

Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia.

Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data.

The Cognitive Assessment Interview (CAI): reliability and validity of a brief interview-based measure of cognition.

Clues to the cognitive and perceptual origins of social isolation and psychosis in schizophrenia.

A randomized controlled trial of allopurinol vs. placebo added on to antipsychotics in patients with schizophrenia or schizoaffective disorder.

Feasibility and pilot efficacy results from the multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) randomized controlled trial.

Validation of a clinician questionnaire to assess reasons for antipsychotic discontinuation and continuation among patients with schizophrenia.

Persistent cannabis users show neuropsychological decline from childhood to midlife.

Cognitive impairment in schizophrenia.

Standardizing the use of the Continuous Performance Test in schizophrenia research: a validation study.

How specific are negative symptoms and cognitive impairment in schizophrenia? An analysis of PANSS and SCoRS.

Formulation of the age-education index: measuring age and education effects in neuropsychological performance.

The course of cognitive functioning over six months in individuals at clinical high risk for psychosis.

Applicability of the MATRICS Consensus Cognitive Battery in Singapore.

Interview-based assessment of cognition in schizophrenia: applicability of the Schizophrenia Cognition Rating Scale (SCoRS) in different phases of illness and settings of care.

Cognition in schizophrenia: summary Nice Consultation Meeting 2012.

Neuropsychological impairments in schizophrenia and psychotic bipolar disorder: findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study.

Altered Striatal Functional Connectivity in Subjects With an At-Risk Mental State for Psychosis.

Defining a clinically meaningful effect for the design and interpretation of randomized controlled trials.

Brief Assessment of Cognition in Schizophrenia: Normative Data in an English-Speaking Ethnic Chinese Sample.

Schizophrenia is a cognitive illness: time for a change in focus.

Social cognition as a mediator between neurocognition and functional outcome in individuals at clinical high risk for psychosis.

Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia.

Neuropsychological decline in schizophrenia from the premorbid to the postonset period: evidence from a population-representative longitudinal study.

Microvascular abnormality in schizophrenia as shown by retinal imaging.

Preserved working memory and altered brain activation in persons at risk for psychosis.

Elevated Antisaccade Error Rate as an Intermediate Phenotype for Psychosis Across Diagnostic Categories.

Unraveling the relationship between obesity, schizophrenia and cognition.

The Longitudinal Youth at Risk Study (LYRIKS)--an Asian UHR perspective.

Validation of the Persian version of the brief assessment of cognition in schizophrenia in patients with schizophrenia and healthy controls.